Detection of cervical cancer recurrence during follow-up: A multivariable comparison of 9 frequently investigated serum biomarkers

Gynecologic Oncology

Volumn 131, Issue 3, 2013, Pages 655-660

  Hoogendam, Jacob P ^a   Zaal, Afra ^a   Rutten, Emma G G M ^a   Heijnen, Cobi J ^b   Kenter, Gemma G ^c   Veldhuis, Wouter B ^a   Verheijen, René H M ^a   Zweemer, Ronald P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Center of Gynaecologic Oncology Amsterdam   (Netherlands)

Author keywords

Biomarker; Cervical cancer; hsCRP; Recurrence; SCC Ag; Serum

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; HIGH SENSITIVITY C REACTIVE PROTEIN; INTERLEUKIN 6; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOLUMINESCENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; UTERINE CERVIX CARCINOMA;

BIOMARKER; CERVICAL CANCER; HSCRP; RECURRENCE; SCC-AG; SERUM;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84888306628     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.10.016     Document Type: Article

References (32)

1. M. Friedlander, and M. Grogan Guidelines for the treatment of recurrent and metastatic cervical cancer Oncologist 7 4 2002 342 347
2. C.A. Perez, P.W. Grigsby, H.M. Camel, A.E. Galakatos, D. Mutch, and M.A. Lockett Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of uterine cervix: update of a nonrandomized comparison Int J Radiat Oncol Biol Phys 31 4 Feb 15 1995 703 716
3. H. Fagundes, C.A. Perez, P.W. Grigsby, and M.A. Lockett Distant metastases after irradiation alone in carcinoma of the uterine cervix Int J Radiat Oncol Biol Phys 24 2 1992 197 204
4. S.E. Waggoner Cervical cancer Lancet 361 2003 2217 2225
5. G. Dreyer, L.C. Snyman, A. Mouton, and B.G. Lindeque Management of recurrent cervical cancer Best Pract Res Clin Obstet Gynaecol 19 4 Aug 2005 631 644
6. E. Wiebe, L. Denny, and G. Thomas FIGO Cancer Report 2012: cancer of the cervix uteri Int J Gynaecol Obstet 119 Suppl. 2 Oct 2012 S100 S109
7. L. Elit, A.W. Fyles, M.C. Devries, T.K. Oliver, M. Fung-Kee-Fung, and Gynecology Cancer Disease Site Group Follow-up for women after treatment for cervical cancer: a systematic review Gynecol Oncol 114 3 Sep 2009 528 535
8. V. Zanagnolo, L.A. Minig, A. Gadducci, T. Maggino, E. Sartori, and P. Zola Surveillance procedures for patients for cervical carcinoma: a review of the literature Int J Gynecol Cancer 19 3 Apr 2009 306 313
9. K.C. Lim, R.E. Howells, and A.S. Evans The role of clinical follow-up in early stage cervical cancer in South Wales BJOG 111 12 Dec 2004 1444 1448
10. A. Ansink, A. De Barros Lopes, R. Naik, and J.M. Monaghan Recurrent stage IB cervical carcinoma: evaluation of the effectiveness of routine follow-up surveillance BJOG 103 11 1996 1156 1158
11. J.M. Duk, H.W. de Bruijn, K.H. Groenier, H. Hollema, K.A. ten Hoor, and M. Krans Cancer of the uterine cervix: sensitivity and specificity of serum squamous cell carcinoma antigen determinations Gynecol Oncol 39 2 Nov 1990 186 194
12. H.Y. Ngan, A.N. Cheung, I.J. Lauder, L.C. Wong, and H.K. Ma Prognostic significance of serum tumour markers in carcinoma of the cervix Eur J Gynaecol Oncol 17 6 1996 512 517
13. S.M. Yoon, K.H. Shin, J.Y. Kim, S.S. Seo, S.Y. Park, and S.H. Moon Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy Radiat Oncol 5 Sep 15 2010 78
14. A. Gadducci, R. Tana, A. Fanucchi, and A.R. Genazzani Biochemical prognostic factors and risk of relapses in patients with cervical cancer Gynecol Oncol 107 Oct 2007 S23 S26 [Sucppl]
15. T.C. Chang, K.S. Law, J.H. Hong, C.H. Lai, K.K. Ng, and S. Hsueh Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study Cancer 101 1 Jul 1 2004 164 171
16. E. Pras, P.H. Willemse, A.A. Canrinus, H.W. de Bruijn, W.J. Sluiter, and K.A. ten Hoor Serum squamous cell carcinoma antigen and CYFRA 21-1 in cervical cancer treatment Int J Radiat Oncol Biol Phys 52 1 Jan 1 2002 23 32
17. F. Forni, G. Ferrandina, F. Deodato, G. Macchia, A.G. Morganti, and D. Smaniotto Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness Int J Radiat Oncol Biol Phys 69 4 Nov 15 2007 1145 1149
18. M.D. Esajas, J.M. Duk, H.W. de Bruijn, J.G. Aalders, P.H. Willemse, and W. Sluiter Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer J Clin Oncol 19 19 Oct 1 2001 3960 3966
19. B.K. Jeong, S.J. Huh, D.H. Choi, W. Park, D.S. Bae, and B.G. Kim Prognostic value of different patterns of squamous cell carcinoma antigen level for the recurrent cervical cancer Cancer Res Treat 45 1 Mar 2013 48 54
20. B.K. Jeong, D.H. Choi, S.J. Huh, W. Park, D.S. Bae, and B.G. Kim The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix Radiat Oncol J 29 3 Sep 2011 191 198
21. W. Jeon, H.K. Koh, H.J. Kim, H.G. Wu, J.H. Kim, and H.H. Chung Salvage radiotherapy for lymph node recurrence after radical surgery in cervical cancer J Gynecol Oncol 23 3 Jul 2012 168 174
22. K.N. Gaarenstroom, J.M. Bonfrer, C.M. Korse, G.G. Kenter, and P. Kenemans Value of CYFRA 21-1, TPA, and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer Anticancer Res 17 4B Jul-Aug 1997 2955 2958
23. L.M. McShane, D.G. Altman, W. Sauerbrei, S.E. Taube, M. Gion, and G.M. Clark REporting recommendations for tumour MARKer prognostic studies (REMARK) Br J Cancer 93 4 Aug 22 2005 387 391
24. M.H. Zweig, and G. Campbell Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine Clin Chem 39 1993 561 577
25. K. Linnet, P.M. Bossuyt, K.G. Moons, and J.B. Reitsma Quantifying the accuracy of a diagnostic test or marker Clin Chem 58 9 Sep 2012 1292 1301
26. G.C. Torre SCC antigen in malignant and nonmalignant squamous lesions Tumour Biol 19 6 1998 517 526
27. J.M. Duk, P.C. van Voorst Vader, K.A. ten Hoor, H. Hollema, H.M. Doeglas, and H.W. de Bruijn Elevated levels of squamous cell carcinoma antigen in patients with a benign disease of the skin Cancer 64 8 Oct 15 1989 1652 1656
28. Y.M. Chan, T.Y. Ng, H.Y. Ngan, and L.C. Wong Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol 84 1 Jan 2002 7 11
29. M. Maiman The clinical application of serum squamous cell carcinoma antigen level monitoring in invasive cervical carcinoma Gynecol Oncol 84 1 Jan 2002 4 6
30. M. Höckel, L.C. Horn, and J. Einenkel (Laterally) extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy Gynecol Oncol 127 2 Nov 2012 297 302
31. G.J. Rustin, M.E. van der Burg, C.L. Griffin, D. Guthrie, A. Lamont, and G.C. Jayson Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial Lancet 376 9747 Oct 2 2010 1155 1163
32. Clinicaltrials.gov register, part of the U.S. National Institutes of Health (http://www.clinicaltrials.gov). Search syntax: "SCC" AND "cervical cancer". Retrieved: May 2nd 2013.